The Claim
Apigenin inhibits CD38 enzyme activity in vitro, with an IC50 of approximately 10.3 μmol/L for NAD+ase activity and 12.8 μmol/L for ADP-ribosyl cyclase activity, demonstrating a direct biochemical interaction.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Apigenin directly reduces the activity of the CD38 enzyme in laboratory cell experiments, with measurable inhibition concentrations of 10.3 μmol/L for NAD+ase and 12.8 μmol/L for ADP-ribosyl cyclase.
See the scientific wording
Apigenin inhibits CD38 enzyme activity in vitro with an IC50 of approximately 10.3 μmol/L for NAD+ase activity and 12.8 μmol/L for ADP-ribosyl cyclase activity, demonstrating direct biochemical interaction.
Apigenin binds to the CD38 enzyme and stops it from breaking down NAD+, causing NAD+ levels to rise inside cells. Higher NAD+ levels activate SIRT1, which removes acetyl groups from proteins involved in metabolism, leading to improved fat burning and better blood sugar control.
What the research says
1 studyStudy: Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38
In lab tests, apigenin was shown to directly block the CD38 enzyme from breaking down NAD+, just like the claim says — and it does so at about the same strength (around 10 micromolar).
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.